Future Horizons in the Treatment of Myelodysplastic Syndromes

Panelists discuss how the future treatment landscape for myelodysplastic syndromes (MDS) appears promising with several ongoing clinical trials exploring novel combinations and targeted therapies, including investigations of venetoclax combinations, magrolimab, sabatolimab, and other immune-based approaches that could potentially improve outcomes across different risk groups and molecular subtypes.

EP: 1.Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

EP: 2.MDS Treatment Strategies: From Risk Assessment to Transplantation

EP: 3.Introducing Hypomethylating Agents for Patients With MDS

EP: 4.ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS

EP: 5.Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS

EP: 6.Clinical Insights: Key Data Presented at ASH 2024 in MDS

EP: 7.A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status

Now Viewing

EP: 8.Future Horizons in the Treatment of Myelodysplastic Syndromes

Video content above is prompted by the following:

• How do you envision the future landscape for the treatment of patients with MDS?
• What ongoing studies on the horizon are you excited about?

Related Videos